MedTrace Logo

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

NCT03703427 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-10-12

No results posted yet for this study

Summary

This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

Conditions

  • Pathologic Residual Cancer Cells

Interventions

DRUG

Capecitabine, Oral, 500 Mg

1250mg/m2，d1-d14，q3w

DRUG

Vinorelbine Tartrate Oral

60mg/m2，d1；d8；q3w

Sponsors & Collaborators

  • Zhiyong Yu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2023-11-30
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03703427 on ClinicalTrials.gov